RXRX at a glance
RECURSION PHARMACEUTICALS, INC. (RXRX, SEC CIK 1601830) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), RECURSION PHARMACEUTICALS, INC. (RXRX) reported revenue of $74.7 million (up 26.9% from FY2024) and a net loss of $644.8 million. Diluted EPS was -$1.44.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding RECURSION PHARMACEUTICALS, INC. (RXRX) shares worth $945.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Borgeson Blake on November 3, 2026 of 40,000 shares at $3.88 per share.
- In the last 90 days, RXRX insiders reported 0 open-market purchases ($0) and 5 open-market sales ($701K) on Form 4, a net sale of $701K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $74.7M
- +26.9% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$701K
- 13F holders
- 34 funds
- $945.0M · +3 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02 · Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: AI-native drug discovery platform integrating biology, chemistry, clinical development to accelerate novel medicine creation
- New emphasis: Clinical validation of Recursion OS in 2025 with positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis (FAP)
- Strategic shift: Pivot from traditional high-attrition “V-shaped” funnel to a ‘T-shaped’ model emphasizing early attrition and AI-driven success probability
- Quantitative highlight: Over $500M partner payments received; 90% fewer compounds synthesized vs industry average; clinical pipeline trimmed to 5 clinical programs in 2025
- Noteworthy fact: First whole-genome CRISPR knockout neuronal and microglial maps created with Roche/Genentech, resulting in $60M milestone payments in 2024-2025
Risk Factors
- FDA regulatory approval risk for all drug candidates currently in discovery or clinical stages, no products approved or commercial revenue as of 2026
- Geopolitical risk from potential U.S. and foreign regulatory reviews on foreign investments, possibly limiting strategic alliances with international partners
- Supply chain vulnerability linked to disruptions impacting clinical trial enrollment, manufacturing capacity, and timing of research activities
- Competitive risk from industry consolidation reducing potential collaborators and increasing competition in neuroscience and oncology drug discovery
- Financial risk of $2.1 billion accumulated deficit as of 12/31/2025 with ongoing need to raise capital through equity offerings, risking shareholder dilution
Management Discussion & Analysis
- Revenue $74.7M in 2025, up 27% YoY from $58.8M driven by Sanofi partnership; 2024 revenue rose 32% from $44.6M primarily from Roche partnership
- Operating margin negative 868% (loss $648.1M on revenue $74.7M) worsening from 815% in 2024 (loss $479.0M on $58.8M revenue)
- Best segment: Research & Development expenses $475.3M up 51.2% YoY, driven by platform costs, Tempus record purchases ($49.9M), and Exscientia acquisition ($102.4M)
- Worst segment: General & Administrative flat at $176.6M in 2025, down 0.9% YoY, but still a substantial cost burden
- Cash flow: Operating cash outflow $371.8M increased; Financing inflow $521.5M mainly from equity sales; Cash & equivalents $753.9M end 2025
- Capital allocation: Raised $957.1M net proceeds from stock since 2023; no product revenue yet; no buybacks or dividends reported
- Outlook: Management plans multiple clinical data readouts and FDA engagement in 2026; key risk includes need for future capital raises; full valuation allowance maintained on Canadian DTAs
AI summary of the RXRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes disclosed from the 2025 Annual Report risk factors
- Key carried-forward risk: common stock investment involves a high degree of risk
- Detailed risks remain in Part I, Item 1A of the 2025 Annual Report
Management Discussion & Analysis
- Quarterly revenue $18.6M, up over 100% YoY from $5.2M, driven by a $10.0M Sanofi milestone
- Net loss $119.0M vs $162.3M YoY, with operating loss $123.2M vs $172.2M
- Best R&D performer: REC-4881 spending $5.8M, up over 100% YoY; worst: internal and partnered discovery, $8.7M, down 75%
- Cash, equivalents and restricted cash $561.5M vs $753.9M at December 31, 2025; operating cash use $264.5M
- Registrational REC-4881 trial anticipated in second half of 2027; additional financing expected in the future
AI summary of the RXRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $18.6M, up from $5.2M, driven by a $10.0M Sanofi milestone payment
- Cash $561.5M at September 30, rising to approximately $748.7M pro forma after the October offering, extending runway into 2029
Item EX-99.2: Item EX-99.2
- Fred Hassan appointed Board Chair effective October 31, 2026
- Veteran pharmaceutical operator brings experience advancing medicines through development, approval and commercial launch
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announcement for the quarter ended September 30, 2026
- Financial details and operating results contained in Exhibit 99.1 press release
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Fred Hassan appointed Board Chair and Class II director, effective October 31, 2026
- Board expanded from 9 to 10 members, signaling added leadership capacity and governance oversight
Item 7.01: Regulation FD Disclosure
- Press release announces Hassan’s appointment as Board Chair, indicating a leadership transition with potential governance and strategic implications
- CGA-IGC conference data release provides new clinical or research updates, potentially affecting pipeline valuation and investor expectations
Item EX-99.3: Item EX-99.3
- Phase 2 TUPELO data strengthen REC-4881’s efficacy case: 87% of patients reduced total polyp burden, with a 47% median reduction after 12 weeks
- Durability supports potential intermittent dosing: 85% remained below baseline 12 weeks after treatment stopped
Item EX-99.4: Item EX-99.4
- Sanofi optioned a potential first-in-class oral immunology candidate, triggering a $10M milestone and validating Recursion’s AI-enabled discovery platform
- Recursion received $144M in cumulative Sanofi upfront and milestone payments, with potential for more than $300M additional milestones and double-digit royalties
Item 2.02: Results of Operations and Financial Condition
- Preliminary September 30 cash, equivalents and restricted cash: approximately $561 million
- $86 million net proceeds from selling 23,696,330 Class A shares through the ATM program
Item 1.01: Entry into a Material Definitive Agreement
- Equity offering: 61.54 million Class A shares at $3.25 per share
- Gross proceeds approximately $200 million before underwriting discounts and expenses
Item EX-99.2: Item EX-99.2
- $200M oversubscribed equity offering extends expected cash runway into 2029, but increases share-count dilution risk
- REC-4881 delivered 47% median total polyp reduction after 12 weeks, with 85% remaining below baseline after treatment cessation
Item 8.01: Other Events
- Sanofi optioned the first collaboration candidate, triggering a $10M milestone and bringing cumulative upfront and milestone payments to $144M
- Recursion remains eligible for over $300M in additional program milestones plus low-double-digit royalties, supporting non-dilutive partnership economics
Item EX-99.4: Item EX-99.4
- $200 million gross equity raise, funding Recursion’s clinical pipeline and operations before underwriting costs
- 61.54 million Class A shares priced at $3.25, creating material dilution for existing shareholders
Item EX-99.1: Item EX-99.1
- Sanofi optioned Recursion’s first collaboration development candidate, validating platform output and moving the program toward clinical development
- $10M milestone payable in Q3 2026, bringing cumulative Sanofi upfront and milestone payments to $144M
Item 7.01: Regulation FD Disclosure
- Sanofi optioned a Recursion development candidate, signaling potential partnership validation and future deal economics
- General corporate update released, with material operating details in Exhibit 99.2
Item 1.01: Entry into a Material Definitive Agreement
- Tempus agreement extended from five to six years, while Recursion loses its convenience-termination right
- Annual license fees reduced to $14M in years three, four, and five from prior amounts up to $42M
AI summaries of RXRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RXRX
Don't miss the next RXRX filing
- Alerts as it files. A push when RXRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RXRX, by share count.
- Ask anything. An AI agent that reads every RXRX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hallett David | F | Nov 16, 2026 | 26,657 | $3.19 |
| Khan Najat | F | Nov 16, 2026 | 85,815 | $3.19 |
| Taylor Ben R | F | Nov 16, 2026 | 25,018 | $3.19 |
| Borgeson Blake | Sell | Nov 3, 2026 | 40,000 | $3.88 |
| Hassan Fred | A | Nov 2, 2026 | 156,658 | - |
| HERSHBERG ROBERT | M | Oct 6, 2026 | 25,000 | $2.22 |
| HERSHBERG ROBERT | M | Oct 6, 2026 | 25,000 | $2.22 |
| HERSHBERG ROBERT | Sell | Oct 6, 2026 | 25,000 | $5.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $44.6M | $58.8M | $74.7M |
| Operating Income | - | -$479.0M | -$648.1M |
| Net Income | -$328.1M | -$463.7M | -$644.8M |
| Op. Margin | - | -814.1% | -867.9% |
| Net Margin | -736.0% | -788.0% | -863.4% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.5B |
| Equity | - | $1.0B | $1.1B |
| ROE | - | -44.8% | -57.0% |
| Per Share | |||
| EPS | $-1.58 | $-1.69 | $-1.44 |
| Cash Flow | |||
| Operating CF | - | -$359.2M | -$371.8M |
| CapEx | $12.0M | $13.7M | $6.5M |
Source: XBRL data in RECURSION PHARMACEUTICALS, INC. (RXRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RXRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $945.0M |
| Q2 2026 | 31 | $757.7M |
| Q1 2026 | 32 | $574.3M |
| Q4 2025 | 27 | $749.4M |
| Q3 2025 | 27 | $776.8M |
| Q2 2025 | 31 | $727.9M |
| Q1 2025 | 29 | $615.1M |
| Q4 2024 | 22 | $716.6M |
- T. Rowe Price Group+5.01M (+695%)
- Vanguard Portfolio Management LLC+4.68M (+15%)
- Two Sigma Investments+4.60M (+137%)
- Morgan Stanley+3.48M (+127%)
- ARK Investment Management+3.41M (+8%)
- State Street Corp−4.70M (-14%)
- Goldman Sachs Group−705.6K (-18%)
- JPMorgan Chase & Co−676.7K (-59%)
- Citigroup−500.8K (-58%)
- Wells Fargo & Co−310.6K (-61%)
- Blackstone Group+17.0K
- Marex Group plc+16.3K
- Truist Financial+13.7K
- Ameriprise Financial+10.7K
- FMR LLC (Fidelity)−46.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RXRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 21, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 6, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| SC 13G | Jul 31, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RXRX SEC filings: frequently asked questions
Are RXRX insiders buying or selling?
In the last 90 days, RECURSION PHARMACEUTICALS, INC. (RXRX) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $701,222 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RXRX stock?
As of September 30, 2026, the largest RECURSION PHARMACEUTICALS, INC. (RXRX) holders among the 13F filers tracked by SignalX were BlackRock ($220.9 million), ARK Investment Management ($184.8 million), Vanguard Portfolio Management LLC ($147.9 million), State Street Corp ($123.9 million), Vanguard Capital Management LLC ($95.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RXRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), RECURSION PHARMACEUTICALS, INC. (RXRX) reported revenue of $74.7 million (up 26.9% from FY2024) and a net loss of $644.8 million. Diluted EPS was -$1.44. The figures come from the XBRL data in the 10-K.
What are the main risks in RXRX's latest 10-K?
In the 10-K filed February 25, 2026, RECURSION PHARMACEUTICALS, INC. (RXRX) flagged: FDA regulatory approval risk for all drug candidates currently in discovery or clinical stages, no products approved or commercial revenue as of 2026. Geopolitical risk from potential U.S. and foreign regulatory reviews on foreign investments, possibly limiting strategic alliances with international partners. (AI summary of the Risk Factors section.)
What did RXRX report in its latest 8-K?
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Q3 revenue $18.6M, up from $5.2M, driven by a $10.0M Sanofi milestone payment.
What are the latest RXRX SEC filings?
RECURSION PHARMACEUTICALS, INC. (RXRX) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 18, 2026.
What is RXRX's SEC CIK number?
RECURSION PHARMACEUTICALS, INC. (RXRX)'s SEC Central Index Key (CIK) is 1601830. EDGAR lists every RXRX filing under that number.
Ask anything about RXRX
The research agent reads RXRX's filings, financials, insider trades and 13F holders, then answers with sources.